Knight Therapeutics Inc

Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The company is headquartered in Montreal, Quebec and currently employs 745 full-time employees. The company went IPO on 2014-02-28. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The company finances other life sciences companies and secures product distribution rights for Canada and select international markets. The firm invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. The company develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.